Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073116 | 0.93 | PARP1 (0.62) | TSHRHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL14073051 | 0.86 | PARP1 (0.70) | TSHRHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL14072963 | 0.84 | TSHR (1.00) | TSHRHPGDNPC1ALDH1A1MAPK1 | |
| SCHEMBL14073354 | 0.84 | TSHR (0.55) | TSHRHPGDNPC1RAB9AALDH1A1 | |
| SCHEMBL14073090 | 0.84 | PARP1 (0.55) | TSHRALDH1A1PARP1KMT2A | |
| SCHEMBL179025 | 0.84 | HPGD (0.84) | HPGDNPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL14073046 | 0.83 | TSHR (0.52) | TSHRALDH1A1PARP1KMT2A | |
| SCHEMBL14073212 | 0.83 | PKM (0.59) | TSHRRAB9AALDH1A1PARP1L3MBTL1 | |
| SCHEMBL14073081 | 0.81 | TSHR (0.50) | TSHRALDH1A1PARP1KMT2A | |
| SCHEMBL14073063 | 0.81 | PARP1 (0.54) | TSHRALDH1A1MAPK1PARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | TSHR 4343/4885HPGD 89/4885NPC1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.